IPCA Labs, Cadila Healthcare among 16 Indian pharma firms blacklisted in Nepal

Written by Ruchika Sharma Published On 2022-12-21T15:24:25+05:30 | Updated On 21 Dec 2022 3:24 PM IST

4 Diabetes Medication FDCs including Glimipride Metformin Strength banned by Health Ministry

Kathmandu: In a major setback, Nepal has banned import of medicines from 16 Indian pharmaceutical companies including IPCA Laboratories, Cadila Healthcare, Baba Ramdev promoted Divya Pharmacy for allegedly failing to comply with the World Health Organization's (WHO) Good Manufacturing Practices (GMP).

Nepal's Department of Drug Administration has released a list of 16 Indian pharmaceutical companies. IPCA Labs in South Sikkim and Ahmedabad-based Cadila Healhcare have also been mentioned in the list that do not comply regulatory compliance apart from Divya Pharmacy, which is part of yoga guru Ramdev's business conglomerate Patanjali Ayurved.

Publication of the list by the department, the national regulatory body of the drugs markets, both allopathic and ayurveda, means that medicines manufactured by those companies cannot be imported to Nepal, according to the Kathmandu Post daily.

"After inspection of the manufacturing facilities of the pharmaceutical companies, which had applied to export their products to our country, we have published the list of the companies that do not comply with the WHO's good manufacturing practices," Santosh KC, a Department spokesperson told IANS.

Good manufacturing practice is a system of ensuring that products are constantly produced and controlled according to the set quality standards, said the news report, it is designed to minimise the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product.

In April and July, the Department had sent a team of drug inspectors to India to probe the manufacturing facilities of pharmaceutical companies that had applied to supply their products to Nepal.

Besides Divya Pharmacy, the list also names Radiant Parenterals Ltd., Mercury Laboratories Ltd., Alliance Biotech, Captab Biotec, Aglowmed Limited, Zee Laboratories Ltd, Daffodils Pharmaceuticals Ltd, GLS pharma Limited, Unijules Life Science Ltd, Concept Pharmaceuticals Pvt, Shree Anand Life Sciences Ltd, IPCA laboratories Ltd, Cadila Healthcare Ltd, Dial Pharmaceuticals, Aglowmed Limited, and Mackur laboratories Ltd.

The Department said that, among the Indian companies it has prohibited, some are already registered and some are new. Products of some companies do not comply with the regulatory requirements and some companies do not comply with good manufacturing practices. Among them, some companies' products are used in critical care, dental cartridges, and also vaccines.

The department has also published a list of 46 drug manufacturing companies, which are found to comply with the WHO's good manufacturing practices. Inspecting good manufacturing practices of pharmaceutical companies, both national and foreign, is a regular duty of the Department.

A few months ago, the Department had alerted drug inspectors to step up surveillance to prevent the import and sales of cough syrups manufactured by an Indian pharmaceutical company after scores of children in Gambia died of kidney failure upon allegedly consuming the syrups.

The move followed a global alert by the World Health Organisation about four cough syrups that could have links to the deaths of children in July, August, and September in the West African country.

Read also: Uttarakhand Ayurveda and Unani Licensing Authority revokes ban on production of 5 Patanjali medicines

Divya PharmacyBaba RamdevPatanjaliWHORadiant ParenteralsMercury LabsAlliance Biotech newsCaptab BiotecAglowmedZee LabsDaffodils PharmaGLS pharmaUnijules Life ScienceConcept PharmaShree Anand Life SciencesIPCA labsCadila HealthcareDial PharmaMackur labsnepalwho gmp

Source : with agency inputs

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751